Printer Friendly

NORTH AMERICAN BIOLOGICALS, INC. ALLOWED EUROPEAN PATENT FOR HIVIG: PRODUCT MAY PREVENT HIV TRANSMISSION TO INFANTS

 MIAMI, May 26 /PRNewswire/ -- North American Biologicals, Inc. ("NABI") (NASDAQ: NBIO) today announced that the European Patent Office has allowed a patent on the company's proprietary immune globulin, HIVIG (tm), and the method of producing it. This immune globulin is an experimental globulin which may prevent the transmission of AIDS from HIV-positive mothers to unborn infants. This patent will afford the company patent protection in all major Western European countries.
 "The award of this European patent covering HIVIG is a significant milestone for our Immune Therapy division, and will provide a strong proprietary position as we move forward with the clinical development and commercialization of a product with major clinical and commercial potential," said David J. Gury, NABI's chairman, president and CEO.
 NABI's goal is to test the effectiveness of HIVIG in preventing the transmission of AIDS from HIV-positive mothers to unborn infants in clinical trials. Up to an estimated 45 percent of the infants born to HIV-infected mothers prove to be infected. The World Health Organization estimates that 5 million to 10 million HIV-infected children will have been born by the year 2000 worldwide.
 Immune globulin products such as HIVIG are antibody-laden substances derived from human plasma, used to immunize recipients against a viral or bacterial disease to which they have been exposed. HIVIG is prepared from the plasma of HIV-antibody-positive donors who are healthy and have a strong immune response to the virus. The plasma is extensively tested and processed to inactivate any resident virus. The antibodies within the plasma are then purified and concentrated to prepare for final administration into patients.
 NABI already has patents for HIVIG in Australia and New Zealand and has filed patent applications in a number of other countries throughout the world. An unrelated party holds the patent for similar technology in the United States.
 HIVIG was owned by Abbott Laboratories until late 1992, when NABI obtained all of Abbott's rights and assets associated with HIVIG including commercial rights, existing inventory, Phase I clinical safety data, patent portfolio, equipment, raw material, and manufacturing technology and specifications.
 North American Biologicals, Inc. is one of the world's largest independent providers of human blood plasma elements to the health care industry and is dedicated to improving the quality of human life by providing plasma and plasma-based products for the diagnosis and therapy of immune disorders.
 -0- 5/26/93
 /CONTACT: David J. Gury, president, or Alfred J. Fernandez, vp finance, both of North American Biologicals, Inc., 305-628-0080; Marcia A. Kean, executive vp, or Chris Taylor, account executive, both of Feinstein Partners Inc., 617-577-8110, for North American Biologicals/
 (NBIO)


CO: North American Biologicals, Inc. ST: Florida IN: MTC SU:

DJ -- NE001 -- 2425 05/26/93 11:47 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 26, 1993
Words:451
Previous Article:GREGORY BURDICK ELECTED EXECUTIVE VICE PRESIDENT, CALIFORNIA FEDERAL BANK; WILL HEAD RESIDENTIAL LENDING DIVISION
Next Article:OSF CHALLENGE '93 SCORES MAJOR TRIUMPH FOR OPEN SYSTEMS
Topics:


Related Articles
NORTH AMERICAN BIOLOGICALS REPORTS YEAR-END 1991 RESULTS
NABI SEEKS TO MARKET THIRD VIROCHEQC DIAGNOSTIC PRODUCT; VIROCHEQC I SERVES AS MULTI-CONSTITUENT CONTROL FOR HIV 1&2 AND HEPATITIS MARKERS
An exact science: Jackson T. Stephens Jr. and ExOxEmis on verge of marketing antiseptic drug for AIDS worldwide.
ABBOTT LABORATORIES TRANSFERS HIVIG TO NORTH AMERICAN BIOLOGICALS, INC.
NORTH AMERICAN BIOLOGICALS, INC. CREATES HIVIG PRODUCTION FACILITY; PILOT LAB CONSTRUCTED; COLLECTION CENTER SEEKS SPECIAL LICENSE
NABI ESTABLISHES SCIENTIFIC ADVISORY BOARD WITH IMMUNOLOGISTS, VIROLOGISTS AND PEDIATRICIANS FROM LEADING MEDICAL INSTITUTIONS
NORTH AMERICAN BIOLOGICALS COMPLETES ACQUISITION OF MAJOR PLASMA COMPANY
NORTH AMERICAN VACCINE ANNOUNCES THAT THE U.S. PATENT AND TRADEMARK OFFICE HAS ISSUED A PATENT FOR THE GROUP B STREP TECHNOLOGY LICENSED TO THE...
NORTH AMERICAN BIOLOGICALS, INC. GAINS FIRST-EVER LICENSE TO COLLECT SPECIALTY PLASMA IN GERMANY
Biosyn receives notice of allowance for key patent addition to C31g technology platform.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters